{"title":"Chapter 3: HIV prevention","nid":649,"vid":2888,"created":1636975334,"changed":1640199646,"field_accordian_header":[{"field_accordian":[{"field_title":"3.1 Combination HIV prevention","field_content":"<p><strong>Condoms<\/strong><\/p>\r\n\r\n<p>The correct and consistent use of condoms with condom-compatible lubricants is recommended for all key populations to prevent sexual transmission of HIV and STIs <em>(strong recommendation, moderate-certainty evidence)<\/em>.<\/p>\r\n\r\n<p><strong>Harm reduction<\/strong><\/p>\r\n\r\n<p>All individuals from key populations who inject drugs should have access to sterile injecting equipment through needle and syringe programmes<em> (strong recommendation, low-certainty evidence)<\/em>.<\/p>\r\n\r\n<p>All people from key populations who are dependent on opioids should be offered opioid substitution therapy in keeping with WHO guidance <em>(strong recommendation, low-certainty evidence)<\/em>, including those in prison and other closed settings.<\/p>\r\n\r\n<p>All key populations with harmful alcohol or other substance use should have access to evidence-based interventions, including brief psychosocial interventions involving assessment, specific feedback and advice <em>(conditional recommendation, very-low-certainty of evidence)<\/em>.<\/p>\r\n\r\n<p>People likely to witness an opioid overdose should have access to naloxone and be instructed in its use for emergency management of suspected opioid overdose <em>(strong recommendation, very-low-certainty of evidence)<\/em>.<\/p>\r\n\r\n<p><strong>Voluntary medical male circumcision<\/strong><\/p>\r\n\r\n<p>Voluntary medical male circumcision (VMMC) should continue to be promoted as an additional efficacious HIV prevention option within combination prevention for adolescents 15 years and older and adult men in settings with generalized epidemics to reduce the risk of heterosexually acquired HIV infection <em>(strong recommendation, highcertainty evidence)<\/em>.<\/p>\r\n\r\n<p>The use of WHO-prequalified male circumcision devices is recommended as additional methods of male circumcision in the context of HIV prevention for males ages 15 years and older <em>(conditional recommendation, moderate-certainty evidence)<\/em>.<\/p>\r\n","field_icon":null},{"field_title":"3.2 Pre-exposure prophylaxis for preventing the acquisition of HIV","field_content":"<p><strong>Oral pre-exposure prophylaxis for preventing the acquisition of HIV<\/strong><\/p>\r\n\r\n<p>Oral pre-exposure prophylaxis (PrEP) containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection\u1d43&nbsp;as part of combination HIV prevention approaches <em>(strong recommendation, highcertainty evidence)<\/em>.<\/p>\r\n\r\n<p>\u1d43 See Box 3.2 for reflections on the definition of substantial risk of HIV infection.<\/p>\r\n\r\n<p><strong>PrEP using the dapivirine vaginal ring<\/strong><\/p>\r\n\r\n<p>The dapivirine vaginal ring may be offered as an additional prevention choice for women\u1d43&nbsp;at substantial risk of HIV infection as part of combination prevention approaches <em>(conditional recommendation, moderate-certainty evidence)<\/em>.<\/p>\r\n\r\n<p>\u1d43&nbsp;For the recommendation on the dapivirine vaginal ring, the term women applies to cisgender women, meaning women assigned female at birth. There is no research at this time to support the dapivirine vaginal ring for other populations.<\/p>\r\n","field_icon":null},{"field_title":"3.3 Post-exposure prophylaxis","field_content":"<p><strong>Overall<\/strong><\/p>\r\n\r\n<p>An HIV post-exposure prophylaxis (PEP) regimen with two ARV drugs is effective, but three drugs are preferred <em>(conditional recommendation, low-certainty evidence)<\/em>.<\/p>\r\n\r\n<p><strong>Adults and adolescents<\/strong><\/p>\r\n\r\n<p>TDF + 3TC (or FTC) is recommended as the preferred backbone regimen for HIV PEP <em>(strong recommendation, lowcertainty evidence)<\/em>.<\/p>\r\n\r\n<p>DTG is recommended as the preferred third drug for HIV PEP <em>(strong recommendation, low-certainty evidence)<\/em>.<\/p>\r\n\r\n<p>When available, ATV\/r, DRV\/r, LPV\/r and RAL may be considered as alternative third drug options for PEP <em>(conditional recommendation, low-certainty evidence)<\/em>.<\/p>\r\n\r\n<p><strong>Children*<\/strong><\/p>\r\n\r\n<p>AZT + 3TC is recommended as the preferred backbone regimen for HIV PEP for children 10 years and younger. ABC + 3TC or TDF + 3TC (or FTC) can be considered as alternative regimens <em>(strong recommendation, low-certainty evidence)<\/em>.<\/p>\r\n\r\n<p>DTG is recommended as the preferred third drug for HIV PEP with approved DTG dosing <em>(strong recommendation, lowcertainty evidence)<\/em>.<\/p>\r\n\r\n<p>When available, ATV\/r, DRV\/r, LPV\/r and RAL may be considered as alternative third drug options for PEP <em>(conditional recommendation, low-certainty evidence)<\/em>.<\/p>\r\n","field_icon":null},{"field_title":"3.4 Infant prophylaxis","field_content":"<p><strong>Good practice statement<\/strong><\/p>\r\n\r\n<p>ART should be initiated urgently among all pregnant and breastfeeding women living with HIV, even if they are identified late in pregnancy or postpartum, because the most effective way to prevent HIV vertical transmission is to reduce maternal viral load.\u1d43<\/p>\r\n\r\n<p>\u1d43&nbsp;Whenever possible, all efforts should be made to identify HIV-infected pregnant women early enough to avoid the need for enhanced prophylaxis.<\/p>\r\n\r\n<p>Infants born to mothers with HIV who are at high risk of acquiring HIVb should receive dual prophylaxis with daily AZT and NVP for the first six weeks of life, whether they are breastfed or formula fed <em>(strong recommendation, moderatecertainty evidence)<\/em>.<\/p>\r\n\r\n<p>Breastfed infants who are at high risk of acquiring HIV\u1d47, including those first identified as exposed to HIV during the postpartum period, should continue infant prophylaxis for an additional six weeks (total of 12 weeks of infant prophylaxis) using either AZT and NVP or NVP alone <em>(conditional recommendation, low-certainty evidence)<\/em>.<\/p>\r\n\r\n<p>\u1d47 High-risk infants are defined as those:<\/p>\r\n\r\n<ul>\r\n\t<li>born to women with established HIV infection who have received less than four weeks of ART at the time of delivery; or<\/li>\r\n\t<li>born to women with established HIV infection with viral load &gt;1000 copies\/mL in the four weeks before delivery, if viral load is available; or<\/li>\r\n\t<li>born to women with incident HIV infection during pregnancy or breastfeeding; or<\/li>\r\n\t<li>born to women identified for the first time during the postpartum period, with or without a negative HIV test prenatally.<\/li>\r\n<\/ul>\r\n\r\n<p>Infants of mothers who are receiving ART and are breastfeeding should receive six weeks of infant prophylaxis with daily NVP. If infants are receiving replacement feeding, they should be given four to six weeks of infant prophylaxis with daily NVP (or twice-daily AZT) <em>(strong recommendation, moderate-certainty evidence for breastfeeding infants; strong recommendation, low-certainty evidence for infants receiving only replacement feeding)<\/em>.<\/p>\r\n","field_icon":null}],"field_header":"Combination HIV prevention"}],"field_content_type":{"tid":8,"name":"Accord","class":"accord"}}